Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models

Georgia M. Beasley, Lauren Kahn, Douglas Tyler

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has primarily focused on maximizing drug delivery through a better understanding of pharmacokinetics while maintaining acceptable levels of toxicity. Although other agents continue to be explored as regional chemotherapy agents, melphalan is currently the drug of choice, although temozolomide has demonstrated promising preclinical results. Resistance mechanisms to melphalan and melphalan pharmacokinetics are studied using animal models of HILP and ILI. The addition of modulators to overcome resistance to the traditional chemotherapy regimen may ultimately improve the clinical response in patients with in-transit melanoma of the extremity.

Original languageEnglish (US)
Pages (from-to)731-758
Number of pages28
JournalSurgical Oncology Clinics of North America
Volume17
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Melphalan
Drug Resistance
Extremities
Animal Models
Pharmacokinetics
Drug Therapy
Research
Pharmaceutical Preparations
temozolomide
Melanoma
Perfusion
Dactinomycin

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

@article{2bb9db9658714e24b85937df86d54a3a,
title = "Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models",
abstract = "A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has primarily focused on maximizing drug delivery through a better understanding of pharmacokinetics while maintaining acceptable levels of toxicity. Although other agents continue to be explored as regional chemotherapy agents, melphalan is currently the drug of choice, although temozolomide has demonstrated promising preclinical results. Resistance mechanisms to melphalan and melphalan pharmacokinetics are studied using animal models of HILP and ILI. The addition of modulators to overcome resistance to the traditional chemotherapy regimen may ultimately improve the clinical response in patients with in-transit melanoma of the extremity.",
author = "Beasley, {Georgia M.} and Lauren Kahn and Douglas Tyler",
year = "2008",
month = "10",
doi = "10.1016/j.soc.2008.04.002",
language = "English (US)",
volume = "17",
pages = "731--758",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Current Clinical and Research Approaches to Optimizing Regional Chemotherapy

T2 - Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models

AU - Beasley, Georgia M.

AU - Kahn, Lauren

AU - Tyler, Douglas

PY - 2008/10

Y1 - 2008/10

N2 - A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has primarily focused on maximizing drug delivery through a better understanding of pharmacokinetics while maintaining acceptable levels of toxicity. Although other agents continue to be explored as regional chemotherapy agents, melphalan is currently the drug of choice, although temozolomide has demonstrated promising preclinical results. Resistance mechanisms to melphalan and melphalan pharmacokinetics are studied using animal models of HILP and ILI. The addition of modulators to overcome resistance to the traditional chemotherapy regimen may ultimately improve the clinical response in patients with in-transit melanoma of the extremity.

AB - A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has primarily focused on maximizing drug delivery through a better understanding of pharmacokinetics while maintaining acceptable levels of toxicity. Although other agents continue to be explored as regional chemotherapy agents, melphalan is currently the drug of choice, although temozolomide has demonstrated promising preclinical results. Resistance mechanisms to melphalan and melphalan pharmacokinetics are studied using animal models of HILP and ILI. The addition of modulators to overcome resistance to the traditional chemotherapy regimen may ultimately improve the clinical response in patients with in-transit melanoma of the extremity.

UR - http://www.scopus.com/inward/record.url?scp=49649107394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649107394&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2008.04.002

DO - 10.1016/j.soc.2008.04.002

M3 - Article

C2 - 18722915

AN - SCOPUS:49649107394

VL - 17

SP - 731

EP - 758

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 4

ER -